 |
BioWorld-International-2009-04-08
Struggling UK Stem Cell Said in Need of Therapy
Struggling UK Stem Cell Said in Need of Therapy
LONDON - Stem cell innovation in the UK is at risk because of structural and cultural barriers that stand in the way of translating products into clinical use. (BioWorld International)
KeyNeurotek Gets €8.2M for Overactive Bladder Program
No Abstract
BioWorld International Correspondent
KeyNeurotek Pharmaceuticals AG completed a second closing of an internal Series C round, raising the total value of the deal to €8.2 million (US$10.9 million).
Although no new investors bought into the company, all its "main existing investors" did participate, Magdeburg, Germany-based KeyNeurotek said.
Those include Munich-based Deutsche Venture Capital, IBG Beteiligungsgesellschaft, of Magdeburg, and Bonn-based KfW.